SystImmune, Inc.
Oncology drugs targeting cancer
- Sector
- Biotech
- Headquarters
- REDMOND, WA
- Founded
- 2022
- Latest Form D
- $7.9M, Oct 2024
- Total capital
- $15.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $15.1M
- 2 Form D · last Oct 2024
- 24 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 4
- 36 pending · first 2020
- Rank in peer group#293 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$7.9M
- Private capital raisedForm D · SEC · 1st filing$7.2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#293 · top 20%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Yi ZhuResearcherExecutive Officer, DirectorLinked by 1 patent
- Hai ZhuDirectorNamed in SEC Form D filings
- Jie D'EliaExecutive OfficerNamed in SEC Form D filings
- Suya ZhangDirectorNamed in SEC Form D filings
What it has protected
USPTO · 4 granted of 40- PendingBispecific Antibody-camptothecin Drug Conjugate And Pharmaceutical Use ThereofUSPTOApplication 19431550
- PendingLigand-drug Conjugate And Use ThereofUSPTOApplication 18866163
- PendingBispecific Tetravalent Antibodies and Methods of Making and Using ThereofUSPTOApplication 19311740
Show all 40 patent records
- Bispecific Antibody-camptothecin Drug Conjugate And Pharmaceutical Use ThereofAug 13, 2026 · Application 19431550Pending
- Ligand-drug Conjugate And Use ThereofMay 21, 2026 · Application 18866163Pending
- Bispecific Tetravalent Antibodies and Methods of Making and Using ThereofMar 19, 2026 · Application 19311740Pending
- Bispecific Antibody-camptothecin Drug Conjugate And Pharmaceutical Use ThereofMar 17, 2026 · US 12,577,325Granted
- Bispecific Tetravalent Antibodies and Methods of Making and Using ThereofSep 30, 2025 · US 12,428,483Granted
- Ligand-drug Conjugate Containing Hydrophilic Sugar StructureSep 25, 2025 · Application 18860818Pending
- Anti-human TROP2 Antibody-camptothecin Drug Conjugate And Medical Use ThereofJun 26, 2025 · Application 18716072Pending
- Bispecific Antibody-camptothecin Drug Conjugate And Pharmaceutical Use ThereofFeb 20, 2025 · Application 18710044Pending
- Methods Of Treating Cancer And The Pharmaceutical Compositions ThereofDec 5, 2024 · Application 18693507Pending
- Bispecific Tetravalent Antibodies and Methods of Making and Using ThereofFeb 16, 2021 · US 10,919,977Granted
- Bispecific Tetravalent Antibodies And Methods Of Making And Using ThereofJul 21, 2020 · US 10,717,783Granted
- Bispecific Antibody-like Protein And Methods Of Making And Using ThereofApplication PCTUS2024057936Pending
- Bispecific Tetravalent Antibody Targeting HER2 And HER3Application PCTUS2024057935Pending
- ANTI-DLL3 Antibody And Method Of Making And Using ThereofApplication PCTUS2024055803Pending
- Methods And Compositions For Treating Tumors Using Antibody Camptothecin Drug ConjugatesApplication PCTUS2024050611Pending
- Gnc T-cell Engager And Method Of Making And Using ThereofApplication 63682278Pending
- ANTI-CLAUDIN18.2 Antibody And Method Of Making And Using ThereofApplication PCTUS2024030371Pending
- Biepitopic Tetravalent Antibody Targeting EgfrApplication PCTUS2023073194Pending
- Methods Of Treating Cancer And The Pharmaceutical Compositions ThereofApplication PCTUS2022077490Pending
- Combination Compositions Comprising Antibody-drug Conjugates And Methods Of Using ThereofApplication PCTUS2026017982Pending
- Combination Compositions Comprising Bispecific Antibody-drug Conjugates And Methods Of Using ThereofApplication PCTUS2026017981Pending
- Ligand-nuclide Conjugates And Their Use ThereofApplication PCTUS2026016765Pending
- Asymmetric Antibody-like Proteins And Methods Of Making And Using ThereofApplication PCTUS2026012609Pending
- Anti-bcma Antibody And Method Of Making And Using ThereofApplication PCTUS2026011318Pending
- Bispecific Antibody-like Proteins And Methods Of Making And Using ThereofApplication 63749722Pending
- Anti-bcma Antibody And Method Of Making And Using ThereofApplication 63746237Pending
- Bispecific Tetravalent Antibody Targeting Egfr And HER3Application PCTUS2022075445Pending
- Bispecific Tetravalent Antibodies And Methods Of Makiing And Using ThereofApplication PCTUS2015066951Pending
- Bispecific Tetravalent Antibodies And Methods Of Making And Using ThereofApplication PCTUS2015066952Pending
- ANTI-CD33 Antibody And ANTI-CD33 Antibody-drug Conjugate And Use ThereofApplication 19113132Pending
- ANTI-DLL3 Antibody And Method Of Making And Using ThereofApplication 19587367Pending
- Bispecific Antibody-like Protein And Methods Of Making And Using ThereofApplication 19589788Pending
- Antibody-auristatin Drug Conjugates And Methods Of Making And Using ThereofApplication 19603957Pending
- Bispecific Tetravalent Antibody Targeting HER2 And HER3Application 19589795Pending
- Methods And Compositions For Treating Tumors Using Antibody Camptothecin Drug ConjugatesApplication 19579933Pending
- Anti-claudin 18.2 Antibody-camptothecin Drug Conjugate And Pharmaceutical Use ThereofApplication 19596847Pending
- Auristatin Drug With High-stability Hydrophilic Linking Unit And Conjugate ThereofApplication 19113148Pending
- Antibody-auristatin Drug Conjugates And Pharmaceutical Use ThereofApplication 19603950Pending
- Connecting Units For Ligand-drug Conjugates And Methods Of Making And Using ThereofApplication 19603955Pending
- ANTI-CLAUDIN18.2 Antibody And Method Of Making And Using ThereofApplication 19484159Pending
Related companies, and why
- Icagen-T, Inc.Similar federal contract value in Biotech · null in contracts
- Ankasa Regenerative Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Endogena Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- MINUTRI INC.Similar federal contract value in Biotech · null in contracts
- Paragon Biosciences Qlarity Capital, Inc.Similar federal contract value in Biotech · null in contracts
- DoubleRainbow Biosciences Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .